



Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

| MEMBER'S LAST NAME: | | MEMBER'S FIRST NAME: | |
|---|---------------------------------------|---|--|
| | , chart notes or lab data, t | etely and legibly. Attach any ad o support the authorization req | Iditional documentation that is quest). Information contained in |
| | mornation and c | | ☐ URGENT |
| MEMBER INFORMATION | | | |
| LAST NAME: | | FIRST NAME: | |
| PHONE NUMBER: | | DATE OF BIRTH: | |
| STREET ADDRESS: | | | |
| CITY: | | STATE: ZIP COD | E: |
| PATIENT INSURANCE ID NUI | MBER: | | |
| F YOU ARE NOT THE PATIENT OR THE PRESCRI | IBER, YOU WILL NEED TO SUBMIT A PHI D | EIGHT (LB/KG): ALLER DISCLOSURE AUTHORIZATION FORM WITH THIS F | REQUEST WHICH CAN BE FOUND AT THE |
| PATIENT'S AUTHORIZED REPF AUTHORIZED REPRESENTATIV | VE'S PHONE NUMBER: | - | |
| PRESCRIBER INFORMATION | | 1 | |
| LAST NAME: | | FIRST NAME: | |
| PRESCRIBER SPECIALTY: | | EMAIL ADDRESS: | |
| NPI NUMBER: | | DEA NUMBER: | |
| PHONE NUMBER: | | FAX NUMBER: | |
| STREET ADDRESS: | | | |
| CITY: | | STATE: ZIP COD | E: |
| REQUESTOR (if different than prescriber): | | OFFICE CONTACT PERSON | I: |
| | | | |
| MEDICATION OR MEDICAL | DISPENSING INFORMATION | DN | |
| MEDICATION NAME: | | | |
| DOSE/STRENGTH: | FREQUENCY: | LENGTH OF THERAPY/REFILLS: | QUANTITY: |
| ■ NEW THERAPY | RENEWAL | IF RENEWAL: DATE THERA | APY INITIATED: |
| DURATION OF THERAPY (SPE | ECIFIC DATES): | | |

Continued on next page.







Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

| MEMBER'S LAST NAME: | LEMBER'S LAST NAME: MEMBER'S FIRST NAME: | | | |
|--|--|--------------------------------------|--|--|
| 1. HAS THE PATIENT TRIED ANY OTHE | R MEDICATIONS FOR THIS CONDITION? | YES (if yes, complete below) NO | | |
| MEDICATION/THERAPY (SPECIFY DRUG NAME AND DOSAGE): | DURATION OF THERAPY (SPECIFY DATES): | RESPONSE/REASON FOR FAILURE/ALLERGY: | | |
| 2. LIST DIAGNOSES: | | ICD-10: | | |
| ☐ Type II diabetes☐ Type II diabetes with established card☐ Type II diabetes with Congestive heart | | | | |
| □ Other Diagnosis: | ICD-10 Code(s): | | | |
| | N: PLEASE PROVIDE ALL RELEVANT CLIN | ICAL INFORMATION TO SUPPORT A | | |
| Clinical information: | | | | |
| For patients with Type II diabetes, p | ease answer the following: | | | |
| Is the patient's estimated glomerula Please provide documentation. | r filtration rate (eGFR) below 30 mL/mir | n/1.73 m2? □ Yes □ No | | |
| | jardy) HgbA1C obtained in the past 6 n t 6 months if the patient has not been o | | | |
| Is the patient on dialysis? 🗆 Yes 🗀 | No | | | |
| Is the patient currently on metformi | n?* □Yes □No | | | |
| Does the patient had an inadequate *Please provide documentation | response or intolerance to metform? | □ Yes □ No | | |
| ☐ Estimated glomerular filtration ra | the following contraindication to metfo te (GFR) less than or equal to 30 mL/mi osis, portal hypertension, ascites, and, | n/1.73 m2 | | |
| For patients with Type II diabetes wi | th established cardiovascular disease, | please answer the following: | | |
| | obin A1c level within the past 6months t 6 months if the patient has not been o | | | |
| Does the patient's body mass index | BMI) exceed 45kg/m ² ? ☐ Yes ☐ No | | | |
| Is the patient's estimated glomerula Please provide documentation. | r filtration rate (eGFR) above 30 mL/mii | n/1.73 m2? □ Yes □ No | | |

 $\hbox{@ 2017-2023}$ by Magellan Rx Management, LLC. All Rights Reserved.

Revision Date: 10/15/2023 CAT0122









Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

| MEMBER'S LAST NAME: | MEMBER'S FIRST NAME: | | |
|--|--|--|--|
| Is the patient's medical history positive for at least one | of the following? Yes No | | |
| Please check at least one of the following: | · · | | |
| □ MI or Stroke | | | |
| ☐ Imaging shows single-vessel or multi-vessel coronary | artery disease | | |
| □ Previous coronary revascularization procedure | • | | |
| □ Positive cardiac stress test | | | |
| ☐ Hospital admission for unstable angina | | | |
| | evascularization procedure, limb or foot amputation due | | |
| | tudy showing evidence of more than 50% stenosis in an | | |
| artery, and/or ankle: brachial index equaling less than | • | | |
| | , | | |
| For diagnosis of Type II diabetes with congestive heart f | ailure, please answer the following: | | |
| Does patient have an ejection fraction (EF) equaling 40% | | | |
| , sara a sar | , , , , , , , , , , , , , , , , | | |
| Does patient have an ejection fraction (EF) greater than | 40%? Please provide documentation. | | |
| , | · | | |
| Has patient ever had NYHA class II, III or IV symptoms of | heart failure? ☐ Yes ☐ No <i>Please provide documentation.</i> | | |
| | · | | |
| Does patient's body mass index (BMI) equal less than 45 | kg/m²? □ Yes □ No Please provide documentation. | | |
| | | | |
| Does patient have a NT-proBNP greater than 300 pg/ml? | ⁹ □ Yes □ No <i>Please provide documentation</i> . | | |
| | • | | |
| For patients with A-fib, is the NT-proBNP greater than 90 | 00 pg/ml? ☐ Yes ☐ No Please provide documentation. | | |
| | | | |
| IF NT-proBNP not available, does patient have a BNP >1 | 00 pg/ml without kidney failure? ☐ Yes ☐ No | | |
| Please submit chart documentation. | | | |
| | | | |
| If NT-proBNP not available and patient has kidney failure | e, does patient have a BNP > 200 pg/ml? ☐ Yes ☐ No | | |
| Please submit chart documentation. | | | |
| | | | |
| If NT-proBNP not available and patient has Atrial fibrillat | ion(AF), does patient have a BNP > 150 pg/ml? | | |
| ☐ Yes ☐ No Please submit chart documentation | | | |
| | | | |
| Does the patient have structural heart disease such as o | ne or more of the following:? Yes No | | |
| Please provide documentation from echocardiogram. | | | |
| □ LA width >4.0cm | | | |
| ☐ LA length >5.0 cm | | | |
| □ LA area >20cm2 | | | |
| □ LA volume >55ml | | | |
| ☐ LA volume index >34ml/m2 | | | |
| Does the patient has left ventricular hypertrophy define | d by at least one of the following:? ☐ Yes ☐ No | | |
| Please provide documentation from echocardiogram. | | | |
| □ Septal thickness or posterior wall thickness >1.1 cm | | | |
| □ LV mass index(LVMI) > 115g/m2 for males and > 95 g/m2 for females | | | |
| □ E/e' (mean septal and lateral) > 13 | | | |
| □ e´ (mean septal and lateral) < 9cm/s | | | |

© 2017–2023 by Magellan Rx Management, LLC. All Rights Reserved.

Revision Date: 10/15/2023 CAT0122

Page 3 of 5











Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

| MEMBER'S LAST NAME: | MEMBER'S FIRST NAME: |
|---|---|
| Has patient been hospitalized in the particular of the particular | ast 12 months before starting Synjardy(empagliflozin/metformin)? |
| Is patient on a stable dose of a diuretic | c? 🗆 Yes 🗆 No Please provide documentation. |
| | n, coronary bypass graft surgery or other major cardiovascular surgery, arting Jardiance? Yes No Please provide documentation. |
| Has patient had a heart translplant? | Yes □ No |
| Does patient have acute decompensation | ted heart failure? Yes No |
| - | disease including severe COPD, requiring home oxygen therapy for their ronic oral steroid therapy for treatment of their severe COPD? Yes No |
| Does patient have severe <u>pulmonary of</u> Please submit chart documentation. | disease including primary pulmonary hypertension? ☐ Yes ☐ No |
| significant mitral valve regurgitation ca | or diagnosis causing patient's heart failure symptoms such as patient has ausing the heart failure, any dilated cardiomyopathy, infiltrative myopathy, or viral myocarditis? \Box Yes \Box No |
| Does patient have and eGFR less than | 20 ml/min/1.73 m ² ? □ Yes □ No |
| Does patient require dialysis? Yes | □ No |
| Is patient's heart failure related to any infiltrative disease accumulation disease muscular dystrophy hypertrophic obstructive cardiomy known pericardial restriction valvular disease expected to lead to atrial fib/flutter with a resting heart | surgery |
| | nic kidney disease(CKD), please answer the following: omerular filtration rate(eGFR) ≥20 to <45 mL/min/1.73m²? □ Yes □ No |
| Does the patient have an estimated glo No Please submit chart documentation. | merular filtration rate(eGFR) an eGFR ≥45 to <90 mL/min/1.73m²? □ Yes □ |

© 2017–2023 by Magellan Rx Management, LLC. All Rights Reserved. Revision Date: 10/15/2023 CAT0122

Page 4 of 5








Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

| MEMBER'S LAST NAME: | MEMBER'S FIRST NAME: |
|---|--|
| Does patient have a urinary albumin:creatinine ra No <i>Please submit chart documentation</i> . | atio ≥200 mg/g (or protein:creatinine ratio ≥300 mg/g)? □ Yes □ |
| blocker(ARB)? ☐ Yes ☐ No Please submit chart do | |
| Is an ACEi or ARB contraindicated? ☐ Yes ☐ No Pa | lease submit chart documentation. |
| Does patient have TypeII diabetes AND prior athe >60ml/min/1.73m ² ? ☐ Yes ☐ No Please submit ch | |
| Is patient receiving both an ACEi and an ARB at the | he same time? Yes No |
| Is patient receiving maintenance dialysis? □ Yes | □ No |
| Has the patient received a kidney transplant? \Box \ | ′es □ No |
| Does patient have polycystic kidney disease? \Box Y | es □ No |
| Does patient have Type1 diabetes? ☐ Yes ☐ No | |
| Are there any other comments, diagnoses, sympto physician feels is important to this review? | oms, medications tried or failed, and/or any other information the |
| | |
| Please note: Not all drugs/diagnosis are covered or information is received. | n all plans. This request may be denied unless all required |
| I ' | true and accurate to the best of my knowledge. I understand that |
| information necessary to verify the accuracy of the | nees may perform a routine audit and request the medical information reported on this form. |
| Prescriber Signature or Electronic I.D. Verification: | Date: |
| · , - | transmission contain confidential health information that is legally privileged. If at any disclosure, copying, distribution, or action taken in relian ce on the contents |
| | this information in error, please notify the sender immediately (via return FAX) |

FAX THIS FORM TO: 800-424-7640

MAIL REQUESTS TO: Magellan Rx Management Prior Authorization Program

Attn: CP – 4201 P.O. Box 64811 St. Paul, MN 55164-0811



and arrange for the return or destruction of these documents.

Page 5 of 5

